Radiation lethality enhancement with 9-aminocamptothecin: Comparison to other topoisomerase I inhibitors

International Journal of Radiation Oncology Biology Physics

Volumn 36, Issue 2, 1996, Pages 369-376

  Lamond, John P ^a   Wang, Meizhi ^b   Kinsella, Timothy J ^a   Boothman, David A ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

9 Aminocamptothecin; DNA repair; PLDR; Topoisomerase I

Indexed keywords

9 AMINOCAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; DNA; GYRASE INHIBITOR;

ARTICLE; CELL SURVIVAL; DRUG CONCENTRATION; HUMAN; HUMAN CELL; IONIZING RADIATION; LETHALITY; MELANOMA CELL; PRIORITY JOURNAL; RADIATION DOSE; X IRRADIATION;

EID: 0030249357     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(96)00326-4     Document Type: Article

References (38)

1. 1. Avemann, K.; Knippers, R.; Koller, T. Camptothecin, a specific inhibitor of type I DNA topoisomerase, induces DNA breakage at replication forks. Mol. Cell Biol. 8:3026-3034; 1988.
2. 2. Boothman, D. A. Enhanced malignant transformation is accompanied by increased survival recovery after ionizing radiation in chinese hamster embryo fibroblasts. Radiat. Res. 138:5121-5125; 1994.
3. 3. Boothman, D. A.; Greer, S.; Pardee, A. B. Potentiation of halogenated pyrimidine radiosensitizers in human carcinoma cells by β-lapachone (3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione), a novel DNA repair inhibitor. Cancer Res. 47:5361-5367; 1987.
4. 4. Boothman, D. A.; Pardee, A. B. Inhibition of radiation-induced neoplastic transformation by β-lapachone. Proc. Natl. Acad. Sec. USA 86:4963-4967; 1989.
5. 5. Boothman, D. A.; Schlegel, R.; Pardee, A. B. Anticarcinogenic potential of DNA repair inhibitors. Mutat. Res. 202:393-411; 1989.
6. 6. Boothman, D. A.; Trask, D. K.; Pardee, A. B. Inhibition of potentially lethal DNA damage repair in human tumor cells by β-lapachone, an activator of topoisomerase I. Cancer Res. 49:605-612; 1989.
7. 7. Boothman, D. A.; Wang, M.; Schea, R.; Burrows, H. L.; Strickfaden, S.; Owens, J. K. Posttreatment exposure to camptothecin enhances the lethal effects of x-rays on radioresistant human malignant melanoma cells. Int. J. Radiat. Oncol. Biol. Phys. 24:939-948; 1992.
8. 8. Boscia, R. E.; Korbut, T.; Holden, S. A.; Ara, G.; Teicher, B. A. Interaction of topoisomerase I inhibitors with radiation in cis-diamminedichloroplatinum (II)-sensitive and -resistant cells in vitro and in the FS aII C fibrosarcoma in vivo. Int. J. Cancer 53:118-123; 1993.
9. 9. Chang, A. Y.; Gu, C. Z.; Keng, P.; Sobel, S. Topotecan and etoposide inhibit radiation repair differently than potential lethal damage or sublethal damage repair (Abstr.). Proc. Annu. Meet. Am. Assoc. Can. Res. 33:A2609; 1992.
10. 10. Del Bino, G.; Bruno, S.; Yi, P. N.; Darzynkiewicz, Z. Apoptotic cell death triggered by camptothecin or teniposide. The cell cycle specificity and effects of ionizing radiation. Cell Prolif. 25:537-548; 1992.
11. 11. Del Bino, G.; Lassota, P.; Darzynkiewicz, Z. The S-phase cytotoxicity of camptothecin. Exp. Cell Res. 193:27-35; 1991.
12. 12. Docampo, R.; Lopez, J. N.; Cruz, F. S.; DeSouza, W. Trypanosoma cruzi: Ultrastructural and metabolic alterations of epimastigotes by β-lapachone. Exp. Parasitol. 42:142-149; 1978.
13. 13. Eng, W.; Facette, L.; Johnson, R. K.; Sternglanz, R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol. Pharmacol. 34:755-760; 1988.
14. 14. Falk, S. J.; Smith, P. J. DNA damaging and cell cycle effects of the topoisomerase I poison camptothecin in irradiated human cells. Int. J. Radiat. Biol. 61:749-757; 1992.
15. 15. Giovanella, B. C.; Stehlin, J. S.; Wall, M. E.; Holden, K. G.; Hecht, S. M.; Gallagher, G.; Caranfa, M. J.; McCabe, F. L.; Faucette, L. F.; Johnson, R. K. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246:1046-1048; 1989.
16. 16. Hennequin, C.; Giocanti, N.; Balosso, J.; Favaudon, V. Interaction of ionizing radiation with the topoisomerase I poison camptothecin in growing V-79 and HeLa cells. Cancer Res. 54:1720-1728; 1994.
17. 17. Hirabayashi, N.; Kim, R.; Nishiyama, M.; et al. Tissue expression of topoisomerase I and II in digestive tract cancers and adjacent normal tissues. Proc. Am. Assoc. Cancer Res. (Abstr.) 33:436; 1992.
18. 18. Hsiang, Y.-H.; Hertzberg, R.; Hecht, S.; Liu, L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 260:14873-14878; 1985.
19. 19. Hsaing, Y.-H.; Liu, L. F. Identification of mammary DNA topoisomerase I as an intra cellular target of the anti cancer drug camptothecin. Cancer Res. 48:1722-1726; 1988.
20. 20. Husain, I.; Mohler, J. L.; Seigler, H. F.; Besterman, J. M. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: Demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res. 54:539-546; 1994.
21. 21. Kim, J. H.; Kim, S. H.; Kolozsvary, A.; Khil, M. S. Potentiation of radiation response in human carcinoma cells in vitro and murine flbrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I. Int. J. Radiat. Oncol. Biol. Phys. 22:515-518; 1992.
22. 22. Lamond, J. P.; Wang, M.; Kinsella, T. J.; Boothman, D. A. Concentration and timing dependence of lethality enhancement between Topotecan, a topoisomerase I inhibitor, and ionizing radiation. Int. J. Radiat. Oncol. Biol. Phys. 36:363-370; 1996.
23. 23. Madden, K. R.; Champoux, J. J. Overexpression of human topoisomerase I in baby hamster kidney cells: Hypersensitivity of clonal isolates to camptothecin. Cancer Res. 52:525-532; 1992.
24. 24. Mattern, M. R.; Hoffman, G. A.; McCabe, F. L.; Johnson, R. K. Synergistic cell killing by ionizing radiation and the topoisomerase I inhibitor, Topotecan (SK&F 104864). Cancer Res. 51:5813-5816; 1991.
25. 25. Mattern, M. R.; Mong, S.-M.; Bartus, H. F.; Mirabelli, C. K.; Crooke, S. T.; Johnson, R. K. Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells. Cancer Res. 47:1793-1798; 1987.
26. 26. Musk, S. R.; Steele, G. G. The inhibition of cellular recovery in human tumour cells by inhibitors of topoisomerase. Br. J. Cancer 62:364-367; 1990.
27. 27. Ng, C. E.; Bussey, A. M.; Raaphorst, G. P. Inhibition of potentially lethal and sublethal damage repair by camptothecin and etoposide in human melanoma cells. Int. J. Radiat. Biol. 66:49-57; 1994.
28. 28. Pantazis, P.; Hinz, H. R.; Mendoza, J. T.; Kozielski, A. J.; Williams, L. J.; Stehlin, J. S.; Giovanella, B. C. Complete inhibition of growth followed by death of human melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice by camptothecins. Cancer Res. 52:3980-3987; 1992.
29. 29. Pantazis, P.; Kozielski, A. J.; Vardeman, D. M.; Petry, E. R.; Giovanella, B. C. Efficacy of camptothecin cogeners in the treatment of human breast carcinoma xenografts. Oncol. Res. 5:273-281; 1994.
30. 30. Roffler, S. K.; Chan, V.; Yeh, M. Y. Potentiation of radioimmunotherapv by inhibition of topoisomerase I. Cancer Res. 54:1276-1285; 1994.
31. 31. Rubin, E.; Wood, V.; Barti, A.; Trites, D.; Lynch, C.; Hurwitz, S.; Bartel, S.; Levy, S.; Rosowsky, A.; Toppmeyer, D.; Kufe, D. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-Aminocamptothecin. Clin. Cancer Res. 1:269-276; 1995.
32. 32. Sasai, K.; Oya, N.; Shibata, T.; Murata, R.; Takagi, T.; Abe, M. Effects of SN38 on responses of murine cells to irradiation (Abstr.). Radiat. Res. 43:A215; 1995.
33. 33. Slichenmyer, W. J.; Rowinsky, E. K.; Donehower, R. C.; Kaufmann, S. H. The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst. 85:271-291; 1993.
34. 34. Steele, G. G. Principles for the combination of radiotherapy and chemotherapy. In: Horwich, A., ed. Combined radiotherapy and chemotherapy in clinical oncology. London: Edward Arnold; 1992:14-22.
35. 35. Tamura, K.; Takada, M.; Masuda, N.; Kawase, I.; Okishio, K.; Kudoh, S.; Fukuoka, M. Radiosensitization effect of CPT-11 against human lung tumor xenografts. (Abstr.). Proc. Annu. Meet. Am. Assoc. Can. Res. 36:A3599; 1995.
36. 36. Trask, D. K.; DiDonato, J. A.; Muller, M. T. Rapid detection and isolation of covalent DNA protein complexes: Application to topoisomerase I and II. EMBO J. 3:671-676; 1984.
37. 37. Trask, D. K.; Muller, M. T. Stabilization of type I topoisomerase-DNA covalent DNA/protein complexes: By actinomycin-D. Proc. Natl. Acad. Sci. USA 85:1417-1421; 1988.
38. 38. Van Der Zee, A. G.; Hollema, H.; de Jong, S; Boonstra, H.; Gouw, A.; Willemsz, P. H.; Zijlstra, J. G.; De Vries, E. G. P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res. 51:5915-5920; 1991.